Residue labeling conventions: chemokine residues are designated by the chemokine name in superscript, followed by the one letter code of the amino acid, and the residue index (Uniprot canonical sequence numbering), for example, CCL5 K45; receptor residues use the Ballesteros-Weinstein numbering scheme for transmembrane residues, for example, Y251 6.51 , or are preceded by NT in superscript for N-terminal residues, for example, NT D11. Sulfated tyrosine residues are designated by sY, for example, NT sY14.
The inflammatory chemokine CCL5, which binds the chemokine receptor CCR5 in a two-step mechanism so as to activate signaling pathways in hematopoetic cells, plays an important role in immune surveillance, inflammation, and development as well as in several immune system pathologies. The recently published crystal structure of CCR5 bound to a high-affinity variant of CCL5 lacks the N-terminal segment of the receptor that is posttranslationally sulfated and is known to be important for high-affinity binding. Here, we report the NMR solution structure of monomeric CCL5 bound to a synthetic doubly sulfated peptide corresponding to the missing first 27 residues of CCR5. Our structures show that two sulfated tyrosine residues, sY10 and sY14, as well as the unsulfated Y15 form a network of strong interactions with a groove on a surface of CCL5 that is formed from evolutionarily conserved basic and hydrophobic amino acids. We then use our NMR structures, in combination with available crystal data, to create an atomic model of full-length wild-type CCR5:CCL5. Our findings reveal the structural determinants involved in the recognition of CCL5 by the CCR5 N terminus. These findings, together with existing structural data, provide a complete structural framework with which to understand the specificity of receptor:chemokine interactions.
Introduction
A functional immune system depends on targeted cell migration, which is regulated by the association of chemokines to both chemokine receptors and glycosaminoglycans (GAGs) [1] . Chemokines constitute a family of small secreted proteins (8-10 kDa) that regulate leukocyte trafficking to sites of inflammation and cell repair, thereby playing important roles in angiogenesis and metastasis, which are hallmarks of cancer and leukocyte development [2] . Negatively charged sulfated GAGs, such as heparin sulfate, chondroitin sulfate, and dermatan sulfate, are abundant on cell surfaces and extracellular matrices of several tissues and serve as nucleation sites for chemokine oligomerization and the creation of chemoattractant gradients [3, 4] . Chemokine receptors, found on the surface of circulating leukocytes, bind extracellular chemokines to trigger intracellular G-protein and b-arrestin-signaling pathways. These pathways, in turn, prompt cytoskeletal rearrangements leading to leukocyte motility that follows the chemokine gradient [1] . Besides their role in the immune system, chemokines and chemokine receptors are also exploited by several pathogens, including HIV-1, which uses the chemokine receptor CCR5 as the major coreceptor during fusion with host cells. Clearly, understanding the molecular basis of receptor:chemokine interactions has practical implications in the development of therapies for multiple autoimmune diseases, cancer, and a number of parasite and viral infections.
The approximately 45 chemokines and 22 chemokine receptors expressed in human cells interact promiscuously, with the same chemokine often binding different receptors and vice versa [5] . Given the highly conserved tertiary structures of both chemokines and chemokine receptors, the determinants of specificity must be subtly encoded in the form of small sequence and structural variations. Chemokines are characterized by an unstructured N-terminal region up to a first cysteine residue (at position 10 in CCL5), after which follows an approximately 10-residue flexible loop (Nloop), a short 3 10 -helix, three strands of an antiparallel b-sheet and a single a-helix at the C terminus [5] . The first cysteine in the N-terminal region forms a disulfide bond with a cysteine residue in the 30s loop connecting the two first b-strands, while the second Nterminal cysteine forms a disulfide bridge with a cysteine residue on the third b-strand. These disulfide bridges characterize the chemokine family, while the number and spacing of N-terminal cysteines further subdivide it into multiple subclasses such as C, CC, CXC, and CX 3 C. Chemokine receptors belong to the class A of G-protein-coupled receptors (GPCRs), sharing a conserved architecture comprised of an extracellular N-terminal segment and a membraneembedded core of seven transmembrane helices interspersed with extra-and intracellular loops. The N-terminal segments of chemokine receptors contain several sites available for post-translational modifications, including for tyrosine sulfation [6] . Such sulfation, which is heterogenous [6] , was shown to be necessary for high-affinity binding of both chemokines and viral proteins, such as HIV-1 envelope glycoprotein gp120, and to confer specificity for different ligands [7, 8] .
The interaction between chemokine receptors and chemokines is thought to occur in a two-step process [9] . In the first step of the interaction, the N-terminal segment of the receptor binds to the chemokine core, defining the so-called chemokine recognition site 1 (CRS1). NMR chemical shift mapping showed the receptor N terminus binds to a shallow groove defined mainly by residues of the N-loop and third b-strand [6] . Despite considerable sequence variation, the chemokine-binding surface always contains positively charged residues, likely essential in recognizing the negatively charged receptor sulfated tyrosine residues. Receptor peptides that lacked the post-translational modification were also shown to bind to this same region, albeit considerably more weakly; this highlights the role of other interactions in determining affinity and specificity to this binding region [6] . Moreover, binding of the N-terminal receptor peptide to chemokines was shown to induce spectral changes in regions of the chemokine structure that had been previously mapped as oligomerization sites [6] . Nevertheless, despite all this information and knowledge of the binding region of receptor N termini on chemokines, there are only four structures of these complexes; all determined by NMR: Nt-CCR3 bound to monomeric CCL11 [10] , Nt-CXCR1 bound to dimeric CXCL8 [11] , and Nt-CXCR4 bound to dimeric (LD) [12] and monomeric (LM) [13] CXCL12. Of the four, only CCR3:CCL11 and CXCR4:LD CXCL12 were solved containing sulfated tyrosine residues.
The second step in the binding of chemokines to chemokine receptors involves the penetration of the flexible N-terminal segment of the chemokine into a deep pocket formed by the helical bundle of the receptor. These two regions together with the second extracellular loop of the receptor constitute the second chemokine recognition site (CRS2). Unlike CRS1, whose structures are available only from NMR experiments, atomic details of CRS2 are well known from the high-resolution crystal structures of three receptor:chemokine complexes-CXCR4:vMIP-II [14] , US28:CX3CL1 [15] , and CCL5: 5P7-CCL5 [16] -all solved in the last 2 years. This means that there are no high-resolution structures of full-length receptor:chemokine complexes, containing both CRSs, which could help understand chemokine recognition and binding, and how these events translate to intracellular signaling by the receptor.
As mentioned previously, CCR5 is a chemokine receptor expressed in leukocytes and is the major coreceptor for HIV. CCL5 is a CC chemokine ligand of CCR5 involved in leukocyte trafficking and a natural HIV suppressor; it is also known as RANTES (regulated on activation, normal T cell expressed and secreted). The CCR5:CCL5 system, therefore, constitutes a promising therapeutic avenue for drug development making it an active area of research for both experimental and computational structural biology [17] . The structures of CCR5 bound to the inhibitor maraviroc and to an engineered high-affinity variant of CCL5 (5P7-CCL5) are known from crystallographic studies [18] . The structure of CCL5, in dimeric and oligomeric forms, is known from several crystallography and NMR studies [19, 20] . Chemical shift perturbations measured upon titration of CCL5 with a doubly sulfated Nt-CCR5 (1-25) peptide mapped the binding interface to a contiguous surface consisting of residues C10-H23 of the Nloop, residues R44, K45, R47, and Q48 in the b2-b3 hairpin, and the last b-strand [21] . A more recent study confirmed the importance of these same CCL5 residues in binding a doubly sulfated Nt-CCR5(1-27) peptide [22] . Importantly, although both these studies used constructs of the chemokine that prevented the formation of higher order oligomers of CCL5, there was still a detectable monomer/dimer equilibrium that complicated data collection and interpretation. Together with weak binding and the low solubility of the complex [21] [22] [23] , this likely explains why there is still no high-resolution NMR structure for the Nt-CCR5:CCL5 complex.
Recently, we applied transferred NOE to detect intermolecular interactions between an N-terminal CCR5 peptide and CCL5 and identified a CCL5 double mutant (CCL5(E66S, P9S)) that is mostly monomeric in solution [23] . In the present study, we use this construct to assign 33 pairwise intermolecular NOE interactions to the corresponding protons of doubly sulfated Nt-CCR5 (1-27) and monomeric CCL5. Dihedral angle restraints on CCL5 were obtained after nearly complete sequential and backbone assignment. Together with the intermolecular NOEs, these restraints allowed us to calculate the structure of the complex. Finally, we built a fulllength model of the wild-type CCR5:CCL5 complex by combining our NOE data with the known crystal structure of CCR5:5P7-CCL5. We believe that our structures and full-length model provide a structural framework for future drug development efforts and for understanding the determinants of specificity of receptor:chemokine interactions.
Results
Assignment and secondary structure of CCL5 (P9S) and Nt-CCR5 As supported by previous experimental data [19] and the recent crystal structure of CCR5 bound to a highaffinity CCL5 variant [16] , CCR5 is thought to interact with monomeric CCL5. At micromolar concentrations in solution, wild-type CCL5 self associates to form high-molecular weight aggregates [23, 24] , a characteristic which is problematic for high-resolution NMR structural characterization of the receptor:chemokine interaction. While the E66S mutation of CCL5 prevents higher order oligomerization, it still does not prevent dimerization of the chemokine at the high concentrations required for NMR. To eliminate dimer formation and enable sequential backbone and side-chain assignment without complications from the simultaneous presence of monomeric and dimeric chemokine, we used a previously identified double mutant of CCL5 (E66S, P9S), hereafter referred to as CCL5 (P9S), which was shown to be mostly monomeric under NMR conditions [23] . (1-27), hereafter referred to as Nt-CCR5(1-27), we performed 3D NMR experiments to obtain complete backbone and side-chain assignments for CCL5(P9S), excluding the N-terminal amine. Under the measurement conditions,~90% of CCL5(P9S) is in the bound state [23] enabling us to use the chemical shift data to assess the secondary structure of CCL5(P9S) in the bound state. We used the chemical shifts of HN, Ha, Ca, Cb, and CO to predict a total of 96 backbone (φ, w) and 30 side-chain (v 1 ) torsion angle values with the program TALOS-N [25] . These predictions indicate the presence of four antiparallel b-strands at C10-I15, K25-Y29, V39-T43, and Q48-A51 as well as an a-helix between residues K56 and L65 (data not shown). Except for the first strand (C10-I15), all these secondary structure assignments are in agreement with previously reported crystal and NMR structures of other CCL5 variants [16, 19, 24] .
NOESY and TOCSY spectra were recorded with 13 C and 15 N filters in both F1 and F2 dimensions, to eliminate contributions of CCL5(P9S) and to assign the resonances of the Nt-CCR5(1-27) peptide, under conditions detailed above. Nearly complete backbone and side-chain assignments were obtained for the receptor N-terminal peptide. Due to fast exchange, the peptide resonances represent an average between the free and bound forms but are dominated by the former because of the large peptide excess. Therefore, chemical shifts were not used to assess the conformation of Nt-CCR5 . In contrast, the intramolecular NOEs are dominated by the TRNOE and interactions occurring in the bound state of the peptide since the NOE of the free peptide is rather small at the temperature, the spectra were measured (37°C). These intramolecular NOEs were important constraints in the calculation of the bound structure of Nt-CCR5 (1-27) (see below) Seven NN(i,i + 1) NOEs, one d aN (i, i + 2), 3 d aN (i,i + 3) NOE, and one N,N(i,i + 2) medium-range NOE observed for residues I9-S17 in the double-filtered NOESY provide evidence for the helical propensity of this segment of the peptide. These observations agree with previous studies of the free Nt-CCR5(1-27) peptide, which revealed a tendency to adopt helical conformations at lower temperatures (274 K) and when bound to HIV gp120 [26] .
Structure determination of the Nt-CCR5(1-27): CCL5(P9S) complex
Based on the backbone and side-chain assignments of CCL5(P9S) in the presence of excess doubly sulfated Nt-CCR5(1-27), we obtained a total of 1385 intramolecular NOEs from 15 N-separated NOESY and 13 C-separated NOESY spectra using CYANA [27] . Of these, 199 belonged to Nt-CCR5 , while the remaining 1186 belonged to CCL5(P9S). Details of the NOEs are provided in Tables 1 and 2 . A total of 33 intermolecular NOEs (Table 2) were observed using a recently developed approach that combines the measurements of a 3D isotope-edited/isotope-filtered NOESY spectrum with the TRNOE effect [23] . Of these 33 NOEs, 32 involved the aromatic protons of residues NT sY10, NT sY14, and NT Y15 of the receptor N terminus, defining this region as the core interface of the complex. No interactions were found with NT Y3. Initially, we unambiguously assigned 19 intermolecular NOEs between methyl protons of CCL5(P9S) and the previously mentioned tyrosine residues of the receptor peptide (Table 2 in ref. [23] ) and used these as distance restraints for structure determination using XPLOR-NIH [28] . The initial structure calculations used these and all intramolecular distance restraints, together with 126 CCL5 dihedral angle restraints obtained from TALOS-N predictions and two manually inserted distance constraints for the disulfide bonds of CCL5 (C11-C34 and C12-C50) ( Table 1) . No dihedral angle constraints were used for Nt-CCR5 . After analysis of the 10 lowest energy structures of an initial batch of 50 structures, we added 16 hydrogen bonds that appeared in more than 50% of these structures as additional restraints in subsequent calculations. The remaining 14 NOEs were assigned in an iterative manner during these calculations. The last set of 106 structures was refined in explicit solvent [29] , following the protocol implemented in HADDOCK2.2 [30] , and using all intra-and intermolecular NOEs, hydrogen bond, and dihedral angle restraints. The refined structures satisfy the experimental restraints, with no distance violations larger than 0.5 A. Structurally, the ensemble is well defined, with an average backbone RMSD from the mean of 0.42 AE 0.11
A for Nt-CCR5(1-27) (calculated on residues 9-17) and 0.30 AE 0.02 A for CCL5(P9S) (calculated on residues 9-66). In addition, more than 98% of the residues in these two ranges of residues fall within the allowed or generously allowed regions of the Ramachandran plot (Table 1) .
Solution structure of the Nt-CCR5(1-27):CCL5 (P9S) complex
The ensemble of the 10 lowest energy structures after water refinement is shown in Fig. 1 . The structure of CCL5(P9S) is mostly well defined, except for the N (residues 1-8) and C (residues 67 and 68) termini, and shows all the characteristics of the canonical chemokine fold (Fig. 1A) . Overall, the ensemble of structures agrees with the observed intramolecular NOEs and with the secondary structure predictions from TALOS-N. The only exception is the absence of a b-strand between residues CCL5 C10 and CCL5 I15, predicted by TALOS-N, which in any event is not characteristic of the CC chemokine fold. Like other CC chemokine structures determined in the presence of a receptor Nterminal peptide, there is little structural deviation between CCL5 bound to the CCR5 N-terminal segment and free CCL5. The average backbone RMSD of our ensemble to the high-resolution crystal structure of dimeric CCL5 (PDB ID: 1EQT) [31] is 1.43 AE 0.06 A for residues 6-66 and 0.97 AE 0.07 A for the 32 residues in structured regions. As expected, the largest deviations lie in the N-loop and loops connecting b strands that are part of either the CCL5:CCL5 dimer or Nt-CCR5(1-27):CCL5 interfaces.
Regarding Nt-CCR5(1-27), our measurements yielded mainly intraresidue and sequential NOEs, resulting in an ensemble of structures with significant flexibility (Fig. 1B) . We could, however, assign some NOEs characteristic of a helical conformation in a central region defined by residues NT I9-NT T16, in agreement with previous NMR studies [26] . In our ensemble, residues NT N13-NT Y15 are classified by DSSP [32] as a 3 10 helix in 90% of the structures and as an a-helix in the remaining 10%. The neighboring residues NT sY10, NT D11, NT I12, and NT T16, although not strictly assigned as helical by DSSP, form hydrogen-bonded turns that contribute to a longer helix-like structure, which is further stabilized by intermolecular contacts with CCL5(P9S). Indeed, residues NT P8-NT S17 of Nt-CCR5(1-27) were shown to have a weak helical tendency at low temperatures (274K) that folded into a stable helix when bound to HIV gp120 [26] . The remaining residues of the peptide, NT M1-NT I9 and NT S17-NT Q27, are mostly disordered, consistent with the lack of medium-and long-range intramolecular NOEs as well as of intermolecular NOEs.
As for the binding interface between the two molecules, our 3D-edited/filtered experiment revealed two regions in CCL5(P9S) involved in binding Nt-CCR5(1-27): a first region comprised of residues CCL5 I15-CCL5 I25, containing the N-loop, and a second region comprised of residues CCL5 T43-CCL5 V49, containing the BBXB motif. This is in line with previous NMR studies that measured chemical shift perturbations on CCL5 upon titration of Nt-CCR5 peptides [21, 22] . These two regions form a continuous cleft lined with polar and basic residues, several of which participate in direct electrostatic interactions with the receptor N terminus, mostly NT D11, NT sY10, and NT sY14 (Fig. 1C) . The two sulfate groups point to opposite ends of the cleft, with NT sY10 interacting mainly with the imidazole of CCL5 H23, which is positively charged in our experiments, and the e-ammonium of CCL5 K45; whereas NT sY14 forms a salt-bridge with the Table 2 . List of intermolecular NOEs used in NMR structure calculations.
guanidinium group of CCL5 R17 in nearly all members of the ensemble, in agreement with previous NMR studies [21] . Notably, the (φ,w) angles of NT sY10 are well into the disallowed region of the Ramachandran plot for all members of the ensemble, a distortion likely due to the charged interactions anchoring it to CCL5(P9S). The negatively charged side-chain of NT D11 makes a saltbridge with CCL5 R47, further anchoring the receptor peptide to the chemokine. This is supported by experiments showing that mutating NT D11 causes a 80-100% decrease in CCL5 binding [33, 34] . Besides these charged interactions, the aromatic moieties of both modified tyrosine residues and of NT Y15 make extensive hydrophobic contacts with apolar side-chains on the inside of the chemokine interface cleft, namely CCL5 I15, CCL5 L19, and CCL5 V49, mutation of which have been shown to reduce binding affinity of CCL5 [21, 35] . Data-driven model of the wild-type full-length CCR5:CCL5 structure
In light of the recently published high-resolution structure of CCR5 in complex with an engineered high-affinity CCL5 variant (5P7-CCL5) [16] , we built a fulllength model of the wild-type CCR5:CCL5 complex that includes both sites (CSR1 and CSR2) modeled from very reliable experimental data: intermolecular NOEs for CSR1 and crystal coordinates for CSR2 (see Material and methods).
We used homology modeling and data-driven flexible refinement to generate 500 final full-length models (for details, see Material and methods for details); 495 of these share more than 60% of the pairwise residue contacts at the interface. These 495 models are grouped into a single cluster using a clustering metric that compares the models disregarding regions of the proteins that are not part of the interface (such as the flexible chain termini). The 10 lowest energy models are remarkably similar, with an average backbone RMSD to the mean, calculated for the same regions as the NMR structures of 0.35 AE 0.14 A for CCR5 and 0.25 AE 0.07 A for CCL5 (Table 3 and Fig. 2A) . The interface backbone RMSD to the mean, calculated on all atoms belonging to any residue within 10 A of the binding partner, is 0.58 AE 0. 24 A, reflecting a strong structural conservation of both CRS1 and CRS2 and highlighting the convergence of the calculations and the robustness of the NOE restraints (Table 3) . Overall, the interface and conformation of the N terminus of CCR5 are in accord with the orientation of CCL5 derived from the structure of 5P7-CCL5 in complex with CCR5, in which the first 15 CCR5 residues were not observed [16] . Much like this crystal structure, the conserved motif NT P19-NT C20 of the receptor packs against the conserved disulfide bridge of the chemokine ( CCL5 C11-CCL5 C50). This region, named CSR1.5 [16] , is further stabilized by a hydrogen bond between NT Q21 of CCR5 and CCL5 Q48 of CCL5 in some of our models. The interactions at the CRS1 interface resemble those observed for the NMR structures, which is expected as the same set of restraints was used to calculate both ensembles of structures. Of note is that the sulfated tyrosine residues contribute most of the binding surface by forming several electrostatic contacts with positively charged residues of CCL5 (Fig. 2B) , while their aromatic moieties contact several hydrophobic side-chains inside the binding pocket (Fig. 2C) . As found for CRS2, the interactions resemble those of the wild-type CCR5:CCL5 model built by Zheng and coworkers [16] , with a few significant differences. In our models, the charged terminal amine of CCL5 S1 interacts either with the hydroxyl group of Y251 6.51 or the carbonyl of E283 7.39 , both previously shown to be important to receptor:chemokine binding [34] . In addition, CCL5 CCL5 Y3 is involved in either pstacking or hydrophobic interactions with a cluster of aromatic residues on several receptor transmembrane helices (Fig. 2C ), most notably Y37 1.39 , W86 2.60 , and Y108
3.32 , mutants of which have been shown to diminish or abrogate binding of the chemokine [34, 36] . Finally, it is important to highlight that the sequence of 5P7-CCL5 differs substantially from wild-type CCL5 in its N-terminal segment (only one of the first nine residues of CCL5, CCL5 P2, is conserved). While this might impact the modeling of CRS2, we are confident our model is relevant to the wild-type interactions given its agreement with mutagenesis data.
Discussion
Observation of intermolecular TRNOE enables determination of the structure of the Nt-CCR5 (1-27):CCL5(P9S) complex
In this study, we calculated the structure of monomeric CCL5(P9S) bound to a doubly sulfated peptide corresponding to the first 27 residues of the chemokine receptor CCR5 based on solution NMR data. This is the second structure of a CC chemokine bound to a sulfated peptide of a chemokine receptor and is of particular interest due to the role of CCR5 in HIV-1 infection [33] .
Two critical factors allowed us to observe intermolecular NOEs between Nt-CCR5(1-27) and CCR5 (P9S). First, the P9S mutation, in addition to the E66S mutation, produced a CCL5 construct that is mostly monomeric under NMR conditions. Unlike previous constructs, which existed in a monomer/dimer equilibrium, CCL5(P9S) enabled us to assign our NMR spectra unambiguously. Second, this assignment was possible due to the combination of TRNOE with f1-edited/f2-filtered NOE measurements of CCL5(P9S) in the presence of a large excess of Nt-CCR5(1-27), together with iterative structure calculations. We could assign 33 intermolecular NOEs for the weakly bound monomeric Nt-CCR5(1-27):CCL5(P9S) complex [23] , despite using protein concentrations comparable to the K D of the complex of 70 lM.
Comparing our structures with earlier chemical shift perturbations on CCL5(P9S) upon titration with Nt-CCR5(1-27) [22] shows overall agreement with some differences. Residues CCL5 I15, CCL5 L19, CCL5 K45, and CCL5 R47 showed some of the strongest chemical shift perturbations, in agreement with our structures where they form strong interactions with residues in Nt-CCR5 (1-27). Other residues with significant chemical shift perturbations are located on the N-and b2-b3 loops. Although these residues do not participate in direct interactions with the receptor in our structures, they are part of the scaffold of the groove where the sulfated tyrosine residues dock and are close in sequence to residues that interact with Nt-CCR5(1-27). On the other hand, residue CCL5 V49, for which we measured several NOEs, had not been considered significantly perturbed in the previous study. These observations underline the importance of measuring intermolecular NOEs when calculating the structure of protein complexes. It is our contention that, for the majority of proteins where chemical shift perturbations are measurable, intermolecular NOEs can be detected using the transferred NOE approach [23, 37] . Such pairwise interactions clarify the underlying basis for the chemical shift perturbation and whether it is due to a direct or indirect effect.
Comparison with the NMR structure of Nt-CCR3 (8-23):CCL11
To date, there is only one other known structure of a CC chemokine bound to the sulfated N-terminal [10] . Given that both CCR3 and CCR5 can bind CCL5 and CCL11, it is particularly interesting to compare the structure of both these complexes.
It is important to highlight, however, that our structure of Nt-CCR5(1-27):CCL5 was refined in explicit solvent and using electrostatics and both attractive and repulsive van der Waals energy terms. Traditional NMR structure calculation protocols run in vacuum and often use only a repulsive van der Waals term. These differences might have an impact on the structure, particularly in the orientation and interaction of charged residues. At first glance, there are two obvious differences between Nt-CCR5(1-27):CCL5 and Nt-CCR3(8-23): CCL11 (Fig. 3A,B) : (1) the conformation of the receptor N-terminal peptide and (2) its orientation relative to the chemokine ligand. Our Nt-CCR5(1-27) peptide shows a helical turn between residues NT N13 and NT Y15 and is oriented along the binding pocket of CCL5 C to N terminus, so that its C-terminal residues interact with the N-loop of the chemokine and its Nterminal residues bind the b2-b3 loop. On the other hand, Nt-CCR3(8-23) does not have a well-defined secondary structure and lies along the chemokine-binding pocket in the opposite orientation, from N to C terminus. The differences in conformation between both peptides may be ascribed to the sulfation of different tyrosine residues. In Nt-CCR3 (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) , the sulfation of consecutive residues, CCR3-NT sY16 and CCR3-NT sY17, likely leads to steric and electrostatic repulsion between the side-chains and forces the backbone in this region to adopt a nonstandard turn, while in Nt-CCR5 , the spacing between NT sY10 and NT sY14 allows the formation of a standard helical turn so that both tyrosine residues face the chemokine surface.
Nevertheless, despite the differences in orientation, conformation, and sulfation pattern, the receptor peptides bind equivalent residues on their respective chemokine partners (Fig. 3A,B) (Fig. 2B) . In Nt-CCR3(8-23):CCL11, CCL11 R22 is either hydrogen bonded to the backbone carbonyl of CCR3-NT sY17 or in a cation-p interaction with its aromatic ring.
These observations offer a possible explanation for the promiscuity of both chemokine receptors and chemokine ligands. The dispersion of positive charges around the central hydrophobic core allows chemokines to bind differently sulfated forms of the same receptor or even different receptors. On the other hand, the slight differences in the contacts made by these positively charged residues as well as by some peripheral hydrophobic amino acids are probable Fig. 3 . Sequence and structural conservation of receptor:chemokine CRS1 interactions. Residue-residue contacts at receptor:chemokine interfaces in (A) our Nt-CCR5(1-27):CCL5(P9S) structure and (B) CCR3:CCL11 structure [10] , respectively. Amino acids are colored by character: charged in blue/red, hydrophobic in pink, and sulfated tyrosine residues in gold. Interactions in the schematics are colored according to their physicochemical character: electrostatic in blue, hydrophobic in pink. (C) Alignment of human CC chemokine sequences. Columns are colored if the amino acid character is conserved in at least 60% of the sequences (except for glycine and proline). Asterisks indicate key residues involved in chemokine receptor binding, as shown in our and other NMR structures. The gray box highlights CCR5 binders, identified in [38] , ordered by binding affinity. modulators of both the specificity and affinity of receptor:chemokine interactions.
Interface residues of CCL5(P9S) are structurally and evolutionarily conserved across the CC and CXC chemokine families
In the absence of further structural data, we looked at evolutionary conservation to confirm a potential role of the positively charged and hydrophobic chemokine residues in conferring specificity to receptor:chemokine interactions. To this end, we constructed a multiple sequence alignment of all annotated human CC chemokines deposited in the Uniprot database [38] (Fig. 3C) and assessed the conservation of these residues across other chemokines.
The hydrophobic residues anchoring the two sulfated tyrosines in both Nt-CCR5(1-27):CCL5 and Nt-CCR3(8-23):CCL11 are highly conserved across the CC chemokine family.
CCL5 L19 ( CCL11 I18) is either strictly conserved or replaced by an isoleucine residue, and CCL5 V49 is conserved in 46% of all human sequences or replaced by other hydrophobic amino acids such as isoleucine (35%), phenylalanine (8%), leucine (8%), or alanine (4%). The basic character of residues interacting with the sulfate moieties of Nt-CCR5(1-27) and Nt-CCR3(8-23) is also conserved throughout the family. Residues equivalent to CCL5 R17, CCL5 H23, CCL5 K45, and CCL5 R47 are positively charged in 73%, 47%, 73%, and 88% of the sequences, respectively. The plasticity of interactions at the receptor:chemokine interface is further illustrated by the seemingly weak evolutionary conservation of CCL5 H23. In Nt-CCR5(1-27):CCR5, CCL5 H23 interacts with the sulfate group of NT sY10, while in Nt-CCR3 (8-23):CCL11, the equivalent CCL11 R22 interacts either with the backbone carbonyl or the aromatic ring of CCR3-NT sY17. As such, in other chemokines that have a hydrophobic or aromatic residue at this position (e.g., CCL3 and CCL4), it is reasonable to assume a strong hydrophobic interaction with the aromatic ring of the sulfate tyrosine.
Of the several chemokines interacting with CCR5 whose affinity was determined experimentally in [38] , the weakest interactor is CCL7. Interestingly, CCL7 lacks a positive charge at position 45 (replaced by a leucine residue, like in CCL11), which prevents a proper stabilization of NT sY10. Then, at position 17, CCL7 has a lysine instead of the arginine observed in all other binders, which may contribute to less frequent salt-bridge formation with NT sY14 due to the shorter side-chain. As a result, the weaker affinity of CCL7 to CCR5 can be rationalized in terms of amino acid changes in these critical positions (Fig. 3C) . Conversely, the strongest interactors, CCL3 and CCL4, both have a phenylalanine in place of CCL5 H23 and an arginine in place of CCL5 K45, which might both help stabilize the bound receptor peptide.
The generality of the above types of chemokine receptor contacts is also seen in the CXC family. Despite sequence and structural divergence, the chemokines of the Nt-CXCR1:CXCL8 [11] and both Nt-CXCR4:CXCL12 [12, 13] complexes solved previously have an arginine at position 47 interacting either with a tyrosine residue of their respective receptors-LD CXCR4-NT sY21, LM CXCR4-NT Y21, and CXCR1-NT Y2-or an immediately adjacent aspartate (equivalent to CCR5 D11). Although, in these experiments, only the peptide used to determine the structure of Nt-CXCR4 bound to dimeric (LD) CXCL12 was sulfated, CXCR1-NT Y2 is flanked by negatively charged amino acids, a motif used to predict sulfation sites [39] . Moreover, equivalent residues of CCL5 V49 in CXC chemokines, CXCL12 V49 and CXCL8 L49, form hydrophobic contacts with the aromatic moiety of tyrosine residues that may be sulfated in the receptor. Together with the structures of Nt-CCR5(1-27):CCL5 (P9S) and Nt-CCR3(8-23):CCL11, these observations support and help rationalize the general promiscuity between receptor and chemokine ligands, in particular among the CC family.
Rationalizing the absence of density for the receptor N-terminal segment in crystallography studies
As mentioned in the introduction, the crystal structures of all receptor:chemokine complexes published to date lack most of the N-terminal segment of the receptor, including the critical sulfated tyrosine residue we find responsible for high-affinity binding of the native chemokine ligands. The authors of the structures of CCR5:5P7-CCL5 [16] and US28:CX3CL1 [15] ascribe the lack of density to the flexibility or disorder of the Nterminal segment, while those of CXCR4:vMIP-II [14] suggest the moderate stability of the CRS1 interaction is the culprit. The underlying causes of this apparent flexibility or moderate affinity are, however, never discussed.
It is known that tyrosine sulfation of chemokine receptors in eukaryotes is heterogeneous [6] . As such, at any given time, the cell expresses differentially sulfated chemokine receptors with a narrow range of molecular mass and charge. There are significant differences in binding affinity for CCR5/CCL5 complexes depending on the sulfation pattern of the receptor N terminus [8] . This is true even within monosulfated variants, so it is reasonable to assume that is a generalized feature or receptor:chemokine interactions. Moreover, our analysis of the conformation of chemokine-bound Nt-CCR5(1-27) and comparison to others highlighted the plasticity of receptor N-terminal peptides, particularly Nt-CCR3 (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) , and its likely dependence on the identity of the sulfated tyrosines.
We suggest, therefore, that a plausible cause for the lack of discernible electron density for the sulfate-containing N-terminal region of chemokine receptors in existing crystal structures is the heterogeneous sulfation process that leads to a diverse population with a range of conformations and affinities at CRS1. In fact, in all three crystal structures, the authors resort to different strategies to stabilize the binding of the chemokine to the receptor. In CCR5:5P7-CCL5, the chemokine construct is a highly engineered variant of CCL5 with an anti-HIV potency twice that of PSC-RANTES, itself a variant of CCL5 with twice the affinity for CCR5 as that of the native chemokine [40] . In CXCR4:vMIP-II, the authors engineered a direct disulfide bridge between the receptor and the chemokine ( CXCR4 D187C-v-MIPII W5C) [14] . Finally, in US28: CX3CL1, the viral receptor (US28) is quite promiscuous and naturally forms high-affinity interactions with several human chemokines, even when the N terminus is mostly truncated as in this structure (lacks the first 10 residues) [15] .
In addition to tyrosine sulfation, crystallization conditions and packing may also play a role in displacing the N-terminal segment from its binding site on a chemokine. As noted by the authors, the crystal packing of CCR5:5P7-CCL5 causes the chemokines of neighboring dimers to interact via their N-loop, which is an important binding region in our NMR structure. This crystal packing dislocates the Nt-CCR5 segment from it binding site on the chemokine that could result an increased flexibility. Coupled to the likely mixed population of sulfated receptors, this increased flexibility could impede structure determination of Nt-CCR5.
In contrast to the endogenous expression of the receptors for crystallography, the receptor N-terminal peptides used in the NMR structure determination here and in other studies are either chemically synthetized (Nt-CCR5, Nt-CCR3) or enzymatically sulfated in vitro and purified to give peptides with selected tyrosine sulfation patterns (Nt-CXCR4). This eliminates heterogeneous sulfation patterns in the receptor peptide surrogates. Moreover, NMR is a particularly well-suited technique for structure determination of flexible or disordered proteins. Together, these strategies enabled us to obtain important insights into the interaction of the N terminus of CCR5 with CCL5, which complement the recently solved crystal structure.
An improved model of the wild-type CCR5:CCL5 reconciles experimental data on both CRS1 and CRS2
The recently published crystal structure of CCR5 bound to 5P7-CCL5 enabled us to build a model of the full-length wild-type CCR5:CCL5 complex (Fig. 2A) . The authors of the CCR5:5P7-CCL5 structure also built a wild-type CCR5:CCL5 model, starting at NT N13 and containing sulfated tyrosine residues placed at positions 14 and 15. In these models, the upstream-sulfated tyrosine NT sY14 interacts with CCL5 K45 and CCL5 R47, while NT sY15 forms a saltbridge with CCL5 R17, again capturing key residues on the chemokine surface and interactions that we also observe in our NMR structures and models. The conformation of the Zheng N-terminal receptor is mostly unstructured and thus different from ours, owing either to the different sulfation pattern or to the lack of upstream stabilizing residues such as NT D11. Our NMR restraints derived from the Nt-CCR5 (1-27):CCL5(P9S) interaction allowed us to model with high accuracy the receptor N terminus up to residue NT I9 and more importantly the interaction of the sulfated tyrosine residues with the chemokine. As such, it provides a structural framework with which to understand a large body of experimental data both on the heterogeneity of tyrosine sulfation [8] and on the role of accessory residues on the receptor N terminus, such as NT D11 [33, 34] . More importantly, it provides a high-confidence model to understand the allosteric link between CRS1 and CRS2, which has been documented before but is poorly understood due to the lack of structural data [5] .
In summary, in this study, we report the structure of monomeric CC chemokine 5-CCL5(P9S)-bound to a doubly sulfated chemokine receptor fragmentNt-CCR5(1-27)-as well as a model of the wild-type CCR5:CCL5 complex. Our data and models support the proposed two-site model, rationalize previous literature on the importance of tyrosine sulfation for CCL5 binding, and highlight the existence of a network of contacts between conserved residues that confer both high-affinity and specific binding of receptors to chemokine ligands. Moreover, our CCR5:CCL5 model is the first to reconcile high-resolution structural data for both CRS1 and CRS2, presenting a unique framework to understand the interactions of chemokine receptors with chemokine ligands.
Material and methods

Nt-CCR5(1-27) peptide and CCL5(P9S)
The Nt-CCR5(1-27) peptide sulfated at Y10 and Y14; MDYQVSSPIY(SO3)DINY(SO3)YTSEPAQKINVKQ was synthetized by solid-phase peptide synthesis as described previously [37] . The sulfated peptide was > 95% homogeneous on HPLC and had the expected molecular mass, as judged by ESI-MS. The yield of the peptide was 20-30%. Both HPLC and NMR analysis showed that the sulfated tyrosine moieties were stable over time under the conditions of the NMR experiments. CCL5(P9S) was expressed, labeled, and purified as previously described [23] . 
NMR Samples conditions
NMR assignment
All NMR experiments were measured on a Bruker AVIII800 spectrometer equipped with a 5 mm TCI cryoprobe. For sequential backbone resonance assignments of bound CCL5 (P9S), a standard 3D triple resonance assignment approach was utilized. HNCACB, CBCA(CO)NH, HNCA, and HNCO experiments were acquired on the complex of 15 N-13 C-CCL5(P9S) with fivefold excess of Nt-CCR5 at pH 4.8, 37°C. Side-chain chemical shift assignments were obtained using HCCH-TOCSY, CCH-TOCSY, and HCC (CO)NH-TOCSY experiments on the same complex, but with CCL5(P9S) labeled only with 13 C for the HCCH-TOCSY and CCH-TOCSY experiments. The chemical shift deviations from random coil values were calculated using the random coil values of the Wishart protein database [41] .
Structure calculation of Nt-CCR5:CCL5 complex
The solution structures of the Nt-CCR5(1-27):CCL5(P9S) complex were calculated using XPLOR-NIH [28] . Torsion angle restraints for CCL5(P9S) were obtained from the HN, Ha, Ca, Cb, and CO chemical shifts using TALOS-N [25] . Automatic NOE assignment was performed with CYANA [27] . The resulting NOE restraints were ported to XPLOR-NIH to calculate an initial set of 50 structures that were used to identify errors in the restraints and assignments. Iterative rounds of refinement yielded a total of 126 torsion angle restraints and 1385 interproton distances, 314 of which were intraresidue, 257 sequential, 103 medium-range, and 136 long-range NOEs. NOEs recorded for equivalent protons in methyl groups were used as ambiguous distance restraints in the calculations. The resulting 106 structures were then refined in explicit solvent [29] using the protocol implemented in HADDOCK2.2 [30] . The geometry of the 10 lowest energy structures was assessed and validated using NMR-PROCHECK [42] ( Table 1) .
Modeling the full-length wild-type CCR5:CCL5 complex
We built initial full-length models of the wild-type CCR5: CCL5 complex using the NMR-determined ensemble of Nt-CCR5(1-27):CCL5(P9S) and the recently released crystal structure of CCR5 bound to the high potency HIV entry inhibitor 5P7-CCL5 (PDB ID: 5UIW) [16] . We used all 10 models of the NMR ensemble instead of the minimized average structure to better capture the observed conformational variability in Nt-CCR5 .
The crystallized CCR5 structure contains seven stabilizing mutations and lacks the first 15 amino acids, while the 5P7-CCL5 N terminus differs substantially from wild-type CCL5. The NMR structures contain one mutation on CCR5 (C20A) and two mutations on CCL5-P9S and E66S-inserted to alleviate oligomerization and dimerization. To model CCR5, we took residues 18-316 from the crystal structure, removing the fused rubredoxin and restoring the native ICL3. The N-terminal region (residues 1-17), including the two sulfated tyrosine residues, was taken from each NMR structure. For CCL5, we took residues 1-8 from the crystal structure, to preserve the conformation and orientation of the N terminus relative to the receptor, and the remainder (residues 9-68) from the NMR structures. Despite the low-sequence similarity, the crystal structure of 5P7-CCL5 agrees with pre-existing mutagenesis data for the N-terminal region of CCL5, lending credence to its use as a template to model the wildtype structure.
We used MODELLER v9.18 [43] to restore both wildtype sequences (CCR5 Uniprot AC: P51681; CCL5 Uniprot AC: P13501) and regularize the geometry of the initial models. The optimization used the loopmodel protocol and custom restraints enforcing disulfide bridges in CCR5 (C20-C269 and C101-C178) and CCL5 (C10-C34 and C11-C50). All residues but the connecting regions between the NMR and crystal structures (residues 18-23 in CCR5 and 8-10 in CCL5) were frozen to preserve their native conformations.
The resulting 10 full-length models were refined as an ensemble with HADDOCK (v2.2) [30] , using all measured dihedral angle restraints as well as intra-and intermolecular NOEs as distance restraints. The rigid-body protocol was disabled, while the semiflexible-simulated annealing and explicit solvent molecular dynamics were run with default parameters to generate 500 final models (five per initial model). The N-terminal serine residue of CCL5 was protonated. The refined models were clustered using a fast contact-based interface similarity algorithm [44] and ranked according to the default HADDOCK scoring function, which combines van der Waals, electrostatics, and restraint energies with an empirical desolvation potential [45] and buried surface area.
The refined models were analyzed using HADDOCK built-in routines (for energetics and violation analysis). DSSP [32] was used for secondary structure calculations and Biopython (Bio.PDB) for alignment and RMSD calculations [46, 47] .
Sequence alignment of CC chemokines
To assess the evolutionary conservation of residues in CC chemokines, we collected all sequences deposited in Uniprot [48] under the manually curated intecrine beta (chemokine CC) family and filtered by species (human) and database (SwissProt). We removed two entries belonging to CC-like chemokines: CCL3L1 and CCL4L1. Given the high degree of sequence conservation, the resulting 24 sequences were aligned using Clustal Omega (version 1.2.4) [49] through the EBI web portal [50] .
